Context Therapeutics (CNTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual Meeting scheduled for June 24, 2026, with voting open until June 23, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 10, 2026.
Voting matters and shareholder proposals
Election of seven director nominees to serve until the 2027 Annual Meeting.
Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Approval sought to amend the Certificate of Incorporation to increase authorized common stock from 200,000,000 to 300,000,000.
Proposal to approve adjournment of the meeting if more time is needed to solicit votes for the share increase.
Board of directors and corporate governance
Seven director nominees listed: Philip Kantoff, MD; Martin Lehr; Andy Pasternak; Karen Smith, MD; Jennifer Evans Stacey; Luke Walker, MD; Linda West.
Latest events from Context Therapeutics
- Promising T cell engager pipeline targets high unmet needs in solid tumors with strong early data.CNTX
Corporate presentation - R&D costs rose sharply as focus shifted to CTIM-76 and CT-202, with cash runway into Q4 2027.CNTX
Q2 2026 - Promising T cell engager pipeline shows early efficacy and safety in solid tumors.CNTX
Corporate presentation - 29% response rate and low-grade CRS observed in late-line ovarian cancer patients.CNTX
Study result - Lead T-cell engager shows early promise in ovarian cancer; key data updates expected soon.CNTX
Jefferies Global Healthcare Conference 2026 - Net loss rose to $8.7 million as R&D spending accelerated and cash runway extends into mid-2027.CNTX
Q1 2026 - Key votes include director elections, auditor ratification, and a proposal to increase authorized shares.CNTX
Proxy filing - Key votes include director elections, auditor ratification, and increasing authorized shares.CNTX
Proxy filing - Cash of $66M funds pipeline progress into mid-2027; key clinical data expected in 2026.CNTX
Q4 2025